nach oben

Clinical Reviews in Allergy & Immunology

Erschienen in:

30.09.2015

A Comprehensive Overview on Myositis-Specific Antibodies: New and Old Biomarkers in Idiopathic Inflammatory Myopathy

verfasst von: Minoru Satoh, Shin Tanaka, Angela Ceribelli, S. John Calise, Edward K. L. Chan

Erschienen in: Clinical Reviews in Allergy & Immunology | Ausgabe 1/2017

Einloggen, um Zugang zu erhalten

Abstract

Autoantibodies specific for idiopathic inflammatory myopathy (myositis-specific autoantibodies (MSAs)) are clinically useful biomarkers to help the diagnosis of polymyositis/dermatomyositis (PM/DM). Many of these are also associated with a unique clinical subset of PM/DM, making them useful in predicting and monitoring certain clinical manifestations. Classic MSAs known for over 30 years include antibodies to Jo-1 (histidyl transfer RNA (tRNA) synthetase) and other aminoacyl tRNA synthetases (ARS), anti-Mi-2, and anti-signal recognition particle (SRP). Anti-Jo-1 is the first autoantibodies to ARS detected in 15–25 % of patients. In addition to anti-Jo-1, antibodies to seven other aminoacyl tRNA synthetases (ARS) have been reported with prevalence, usually 1–5 % or lower. Patients with any anti-ARS antibodies are associated with anti-synthetase syndrome characterized by myositis, interstitial lung disease (ILD), arthritis, Raynaud’s phenomenon, and others. Several recent studies suggested heterogeneity in clinical features among different anti-ARS antibody-positive patients and anti-ARS may also be found in idiopathic ILD without myositis. Anti-Mi-2 is a classic marker for DM and associated with good response to steroid treatment and good prognosis. Anti-SRP is specific for PM and associated with treatment-resistant myopathy histologically characterized as necrotizing myopathy. In addition to classic MSAs, several new autoantibodies with strong clinical significance have been described in DM. Antibodies to transcription intermediary factor 1γ/α (TIF1γ/α, p155/140) are frequently found in DM associated with malignancy while anti-melanoma differentiation-associated gene 5 (MDA5; CADM140) are associated with clinically amyopathic DM (CADM) complicated by rapidly progressive ILD. Also, anti-MJ/nuclear matrix protein 2 (NXP-2) and anti-small ubiquitin-like modifier-1 (SUMO-1) activating enzyme (SAE) are recognized as new DM-specific autoantibodies. Addition of these new antibodies to clinical practice in the future will help in making earlier and more accurate diagnoses and better management for patients.

Satoh M, Chan EKL, Sobel ES, Kimpel DL, Yamasaki Y, Narain S, Mansoor R, Reeves WH (2007) Clinical implication of autoantibodies in patients with systemic rheumatic diseases. Expert Rev Clin Immunol 3:721–738PubMedCrossRef

Satoh M, Vazquez-Del Mercado M, Chan EK (2009) Clinical interpretation of antinuclear antibody tests in systemic rheumatic diseases. Mod Rheumatol 19:219–228PubMedPubMedCentralCrossRef

Arbuckle MR, McClain MT, Rubertone MV, Scofield RH, Dennis GJ, James JA, Harley JB (2003) Development of autoantibodies before the clinical onset of systemic lupus erythematosus. N Engl J Med 349:1526–1533PubMedCrossRef

Nishikai M, Reichlin M (1980) Heterogeneity of precipitating antibodies in polymyositis and dermatomyositis. Characterization of the Jo-1 antibody system. Arthritis Rheum 23:881–888PubMedCrossRef

Targoff IN, Reichlin M (1985) The association between Mi-2 antibodies and dermatomyositis. Arthritis Rheum 28:796–803PubMedCrossRef

Targoff IN (1992) Autoantibodies in polymyositis. Rheum Dis Clin N Am 18:455–482

Targoff IN, Mamyrova G, Trieu EP, Perurena O, Koneru B, O’Hanlon TP, Miller FW, Rider LG (2006) A novel autoantibody to a 155-kD protein is associated with dermatomyositis. Arthritis Rheum 54:3682–3689PubMedCrossRef

Fujimoto M, Hamaguchi Y, Kaji K, Matsushita T, Ichimura Y, Kodera M, Ishiguro N, Ueda-Hayakawa I, Asano Y, Ogawa F et al (2012) Myositis-specific anti-155/140 autoantibodies target transcriptional intermediary factor 1 family proteins. Arthritis Rheum 64:513–522PubMedCrossRef

Sato S, Hoshino K, Satoh T, Fujita T, Kawakami Y, Kuwana M (2009) RNA helicase encoded by melanoma differentiation-associated gene 5 is a major autoantigen in patients with clinically amyopathic dermatomyositis: association with rapidly progressive interstitial lung disease. Arthritis Rheum 60:2193–2200PubMedCrossRef

10.

Sato S, Hirakata M, Kuwana M, Suwa A, Inada S, Mimori T, Nishikawa T, Oddis CV, Ikeda Y (2005) Autoantibodies to a 140-kD polypeptide, CADM-140, in Japanese patients with clinically amyopathic dermatomyositis. Arthritis Rheum 52:1571–1576PubMedCrossRef

11.

Hoshino K, Muro Y, Sugiura K, Tomita Y, Nakashima R, Mimori T (2010) Anti-MDA5 and anti-TIF1-{gamma} antibodies have clinical significance for patients with dermatomyositis. Rheumatology (Oxford) 49:1726–1733CrossRef

12.

Nakashima R, Imura Y, Kobayashi S, Yukawa N, Yoshifuji H, Nojima T, Kawabata D, Ohmura K, Usui T, Fujii T et al (2010) The RIG-I-like receptor IFIH1/MDA5 is a dermatomyositis-specific autoantigen identified by the anti-CADM-140 antibody. Rheumatology (Oxford) 49:433–440CrossRef

13.

Targoff IN (2000) Update on myositis-specific and myositis-associated autoantibodies. Curr Opin Rheumatol 12:475–481PubMedCrossRef

14.

Nakashima R, Mimori T (2010) Clinical and pathophysiological significance of myositis-specific and myositis-associated autoantibodies. Int J Clin Rheumatol 5:523–536CrossRef

15.

Targoff IN, Arnett FC (1990) Clinical manifestations in patients with antibody to PL-12 antigen (alanyl-tRNA synthetase). Am J Med 88:241–251PubMedCrossRef

16.

Hirakata M, Suwa A, Nagai S, Kron MA, Trieu EP, Mimori T, Akizuki M, Targoff IN (1999) Anti-KS: identification of autoantibodies to asparaginyl-transfer RNA synthetase associated with interstitial lung disease. J Immunol 162:2315–2320PubMed

17.

Nakashima R, Imura Y, Hosono Y, Seto M, Murakami A, Watanabe K, Handa T, Mishima M, Hirakata M, Takeuchi T et al (2014) The multicenter study of a new assay for simultaneous detection of multiple anti-aminoacyl-tRNA synthetases in myositis and interstitial pneumonia. PLoS ONE 9:e85062PubMedPubMedCentralCrossRef

18.

Love LA, Leff RL, Fraser DD, Targoff IN, Dalakas M, Plotz PH, Miller FW (1991) A new approach to the classification of idiopathic inflammatory myopathy: myositis-specific autoantibodies define useful homogeneous patient groups. Medicine (Baltimore) 70:360–374CrossRef

19.

Targoff IN, Miller FW, Medsger TA Jr, Oddis CV (1997) Classification criteria for the idiopathic inflammatory myopathies. Curr Opin Rheumatol 9:527–535PubMedCrossRef

20.

Satoh M, Chan EK, Ho LA, Rose KM, Parks CG, Cohn RD, Jusko TA, Walker NJ, Germolec DR, Whitt IZ et al (2012) Prevalence and sociodemographic correlates of antinuclear antibodies in the United States. Arthritis Rheum 64:2319–2327PubMedPubMedCentralCrossRef

21.

Rider LG, Shah M, Mamyrova G, Huber AM, Rice MM, Targoff IN, Miller FW (2013) The myositis autoantibody phenotypes of the juvenile idiopathic inflammatory myopathies. Medicine (Baltimore) 92:223–243CrossRef

22.

Trallero-Araguas E, Rodrigo-Pendas JA, Selva-O’Callaghan A, Martinez-Gomez X, Bosch X, Labrador-Horrillo M, Grau-Junyent JM, Vilardell-Tarres M (2012) Usefulness of anti-p155 autoantibody for diagnosing cancer-associated dermatomyositis: a systematic review and meta-analysis. Arthritis Rheum 64:523–532PubMedCrossRef

23.

Frank MB, McCubbin V, Trieu E, Wu Y, Isenberg DA, Targoff IN (1999) The association of anti-Ro52 autoantibodies with myositis and scleroderma autoantibodies. J Autoimmun 12:137–142PubMedCrossRef

24.

Selva-O’Callaghan A, Labrador-Horrillo M, Solans-Laque R, Simeon-Aznar CP, Martinez-Gomez X, Vilardell-Tarres M (2006) Myositis-specific and myositis-associated antibodies in a series of eighty-eight Mediterranean patients with idiopathic inflammatory myopathy. Arthritis Rheum 55:791–798PubMedCrossRef

25.

Ghirardello A, Zampieri S, Tarricone E, Iaccarino L, Bendo R, Briani C, Rondinone R, Sarzi-Puttini P, Todesco S, Doria A (2006) Clinical implications of autoantibody screening in patients with autoimmune myositis. Autoimmunity 39:217–221PubMedCrossRef

26.

Vancsa A, Gergely L, Ponyi A, Lakos G, Nemeth J, Szodoray P, Danko K (2010) Myositis-specific and myositis-associated antibodies in overlap myositis in comparison to primary dermatopolymyositis: relevance for clinical classification: retrospective study of 169 patients. Joint Bone Spine 77:125–130PubMedCrossRef

27.

Chinoy H, Fertig N, Oddis CV, Ollier WE, Cooper RG (2007) The diagnostic utility of myositis autoantibody testing for predicting the risk of cancer-associated myositis. Ann Rheum Dis 66:1345–1349PubMedPubMedCentralCrossRef

28.

Gunawardena H, Betteridge ZE, McHugh NJ (2009) Myositis-specific autoantibodies: their clinical and pathogenic significance in disease expression. Rheumatology (Oxford) 48:607–612CrossRef

29.

Satoh M, Chan JY, Ceribelli A, Del-Mercado MV, Chan EK (2013) Autoantibodies to argonaute 2 (su antigen). Adv Exp Med Biol 768:45–59PubMedCrossRef

30.

Satoh M, Ceribelli A, Hirakata M, Chan EKL (2015) Immunodiagnosis of autoimmune myopathies. In: Detrick B, Hamilton RG, Schmitz JL (eds) Manual of molecular and clinical laboratory immunology, 8th edn. ASM Press, Washington, D. C, In Press

31.

Arnett FC, Hirsch TJ, Bias WB, Nishikai M, Reichlin M (1981) The Jo-1 antibody system in myositis: relationships to clinical features and HLA. J Rheumatol 8:925–930PubMed

32.

Yoshida S, Akizuki M, Mimori T, Yamagata H, Inada S, Homma M (1983) The precipitating antibody to an acidic nuclear protein antigen, the Jo-1, in connective tissue diseases. Arthritis Rheum 26:604–611PubMedCrossRef

33.

Targoff IN, Arnett FC, Reichlin M (1988) Antibody to threonyl-transfer RNA synthetase in myositis sera. Arthritis Rheum 31:515–524PubMedCrossRef

34.

Arnett FC, Targoff IN, Mimori T, Goldstein R, Warner NB, Reveille JD (1996) Interrelationship of major histocompatibility complex class II alleles and autoantibodies in four ethnic groups with various forms of myositis. Arthritis Rheum 39:1507–1518PubMedCrossRef

35.

Bernstein RM, Bunn CC, Hughes GRV, Francoeur AM, Mathews MB (1984) Cellular protein and RNA antigens in autoimmune disease. Mol Biol Med 2:105–120PubMed

36.

Hirakata M, Mimori T, Akizuki M, Craft J, Hardin JA, Homma M (1992) Autoantibodies to small nuclear and cytoplasmic ribonucleoproteins in Japanese patients with inflammatory muscle disease. Arthritis Rheum 35:449–456PubMedCrossRef

37.

Friedman AW, Targoff IN, Arnett FC (1996) Interstitial lung disease with autoantibodies against aminoacyl-tRNA synthetases in the absence of clinically apparent myositis. Semin Arthritis Rheum 26:459–467PubMedCrossRef

38.

Yamasaki Y, Yamada H, Nozaki T, Akaogi J, Nichols C, Lyons R, Chin Loy A, Chan EK, Reeves WH, Satoh M (2006) Unusually high frequency of autoantibodies to PL-7 associated with milder muscle disease in Japanese patients with polymyositis/dermatomyositis. Arthritis Rheum 54:2004–2009PubMedCrossRef

39.

Sato S, Hirakata M, Kuwana M, Nakamura K, Suwa A, Inada S, Mimori T, Ikeda Y (2005) Clinical characteristics of Japanese patients with anti-PL-7 (anti-threonyl-tRNA synthetase) autoantibodies. Clin Exp Rheumatol 23:609–615PubMed

40.

Kalluri M, Sahn SA, Oddis CV, Gharib SL, Christopher-Stine L, Danoff SK, Casciola-Rosen L, Hong G, Dellaripa PF, Highland KB (2009) Clinical profile of anti-PL-12 autoantibody. Cohort study and review of the literature. Chest 135:1550–1556PubMedCrossRef

41.

Labirua-Iturburu A, Selva-O'Callaghan A, Vincze M, Danko K, Vencovsky J, Fisher B, Charles P, Dastmalchi M, Lundberg IE (2012) Anti-PL-7 (anti-threonyl-tRNA synthetase) antisynthetase syndrome: clinical manifestations in a series of patients from a European multicenter study (EUMYONET) and review of the literature. Medicine (Baltimore) 91:206–211CrossRef

42.

Marie I, Josse S, Decaux O, Dominique S, Diot E, Landron C, Roblot P, Jouneau S, Hatron PY, Tiev KP et al (2012) Comparison of long-term outcome between anti-Jo1- and anti-PL7/PL12 positive patients with antisynthetase syndrome. Autoimmun Rev 11:739–745PubMedCrossRef

43.

Marie I, Josse S, Decaux O, Diot E, Landron C, Roblot P, Jouneau S, Hatron PY, Hachulla E, Vittecoq O et al (2013) Clinical manifestations and outcome of anti-PL7 positive patients with antisynthetase syndrome. Eur J Intern Med 24:474–479PubMedCrossRef

44.

Aggarwal R, Cassidy E, Fertig N, Koontz DC, Lucas M, Ascherman DP, Oddis CV (2014) Patients with non-Jo-1 anti-tRNA-synthetase autoantibodies have worse survival than Jo-1 positive patients. Ann Rheum Dis 73:227–232PubMedCrossRef

45.

Hamaguchi Y, Fujimoto M, Matsushita T, Kaji K, Komura K, Hasegawa M, Kodera M, Muroi E, Fujikawa K, Seishima M et al (2013) Common and distinct clinical features in adult patients with anti-aminoacyl-tRNA synthetase antibodies: heterogeneity within the syndrome. PLoS ONE 8, e60442PubMedPubMedCentralCrossRef

46.

Reeves WH, Nigam SK, Blobel G (1986) Human autoantibodies reactive with the signal-recognition particle. Proc Natl Acad Sci U S A 83:9507–9511PubMedPubMedCentralCrossRef

47.

Nakao Y, Mukai R, Kabashima T, Ohshima Y, Hamaguchi H, Kashiwagi H, Okada N (1982) A novel antibody which precipitates 7.5S RNA is isolated from a patient with autoimmune disease. Biochem Biophys Res Commun 109:1332–1338PubMedCrossRef

48.

Okada N, Mimori T, Mukai R, Kashiwagi H, Hardin JA (1987) Characterization of human autoantibodies that selectively precipitate the 7SL RNA component of the signal recognition particle. J Immunol 138:3219–3223PubMed

49.

Targoff IN, Johnson AE, Miller FW (1990) Antibody to signal recognition particle in polymyositis. Arthritis Rheum 33:1361–1370PubMedCrossRef

50.

Kao AH, Lacomis D, Lucas M, Fertig N, Oddis CV (2004) Anti-signal recognition particle autoantibody in patients with and patients without idiopathic inflammatory myopathy. Arthritis Rheum 50:209–215PubMedCrossRef

51.

Hengstman GJ, ter Laak HJ, Vree Egberts WT, Lundberg IE, Moutsopoulos HM, Vencovsky J, Doria A, Mosca M, van Venrooij WJ, van Engelen BG (2006) Anti-signal recognition particle autoantibodies: marker of a necrotising myopathy. Ann Rheum Dis 65:1635–1638PubMedPubMedCentralCrossRef

52.

Miller T, Al-Lozi MT, Lopate G, Pestronk A (2002) Myopathy with antibodies to the signal recognition particle: clinical and pathological features. J Neurol Neurosurg Psychiatry 73:420–428PubMedPubMedCentralCrossRef

53.

Takada T, Hirakata M, Suwa A, Kaneko Y, Kuwana M, Ishihara T, Ikeda Y (2009) Clinical and histopathological features of myopathies in Japanese patients with anti-SRP autoantibodies. Mod Rheuamtol 19:156–164CrossRef

54.

Benveniste O, Drouot L, Jouen F, Charuel JL, Bloch-Queyrat C, Behin A, Amoura Z, Marie I, Guiguet M, Eymard B et al (2011) Correlation of anti-signal recognition particle autoantibody levels with creatine kinase activity in patients with necrotizing myopathy. Arthritis Rheum 63:1961–1971PubMedCrossRef

55.

Aggarwal R, Oddis CV, Goudeau D, Fertig N, Metes I, Stephens C, Qi Z, Koontz D, Levesque MC (2015) Anti-signal recognition particle autoantibody ELISA validation and clinical associations. Rheumatology (Oxford) 54:1194–1199CrossRef

56.

Suzuki S, Nishikawa A, Kuwana M, Nishimura H, Watanabe Y, Nakahara J, Hayashi YK, Suzuki N, Nishino I (2015) Inflammatory myopathy with anti-signal recognition particle antibodies: case series of 100 patients. Orphan J Rare Dis 10:61CrossRef

57.

Vincze M, Molnar PA, Tumpek J, Szollosi L, Gyetvai A, Kapitany A, Danko K (2010) An unusual association: anti-Jo1 and anti-SRP antibodies in the serum of a patient with polymyositis. Clin Rheumatol 29:811–814PubMedCrossRef

58.

Sugie K, Tonomura Y, Ueno S (2012) Characterization of dermatomyositis with coexistence of anti-Jo-1 and anti-SRP antibodies. Intern Med 51:799–802PubMedCrossRef

59.

Malkan A, Cappelen-Smith C, Beran R, Griffith N, Toong C, Wang MX, Cordato D (2015) Anti-synthetase syndrome associated with anti PL-12 and anti-signal recognition particle antibodies and a necrotizing auto-immune myositis. J Clin Neurosci 22:396–398PubMedCrossRef

60.

Satoh T, Okano T, Matsui T, Watabe H, Ogasawara T, Kubo K, Kuwana M, Fertig N, Oddis CV, Kondo H et al (2005) Novel autoantibodies against 7SL RNA in patients with polymyositis/dermatomyositis. J Rheumatol 32:1727–1733PubMed

61.

Ellis E, Ann Tan J, Lester S, Tucker G, Blumbergs P, Roberts-Thomson P, Limaye V (2012) Necrotizing myopathy: clinicoserologic associations. Muscle Nerve 45:189–194PubMedCrossRef

62.

Wang L, Liu L, Hao H, Gao F, Liu X, Wang Z, Zhang W, Lv H, Yuan Y (2014) Myopathy with anti-signal recognition particle antibodies: clinical and histopathological features in Chinese patients. Neuromuscul Disord 24:335–341PubMedCrossRef

63.

Suzuki S, Yonekawa T, Kuwana M, Hayashi YK, Okazaki Y, Kawaguchi Y, Suzuki N, Nishino I (2014) Clinical and histological findings associated with autoantibodies detected by RNA immunoprecipitation in inflammatory myopathies. J Neuroimmunol 274:202–208PubMedCrossRef

64.

Ellis AE, De Sousa M (1974) Phylogeny of the lymphoid system. I. A study of the fate of circulating lymphocytes in plaice. Eur J Immunol 4:338–343PubMedCrossRef

65.

Nilasena DS, Trieu EP, Targoff IN (1995) Analysis of the Mi-2 autoantigen of dermatomyositis. Arthritis Rheum 38:123–128PubMedCrossRef

66.

Zhang Y, LeRoy G, Seelig HP, Lane WS, Reinberg D (1998) The dermatomyositis-specific autoantigen Mi2 is a component of a complex containing histone deacetylase and nucleosome remodeling activities. Cell 95:279–289PubMedCrossRef

67.

Roux S, Seelig HP, Meyer O (1998) Significance of Mi-2 autoantibodies in polymyositis and dermatomyositis. J Rheumatol 25:395–396PubMed

68.

Brouwer R, Hengstman GJ, Vree Egberts W, Ehrfeld H, Bozic B, Ghirardello A, Grondal G, Hietarinta M, Isenberg D, Kalden JR et al (2001) Autoantibody profiles in the sera of European patients with myositis. Ann Rheum Dis 60:116–123PubMedPubMedCentralCrossRef

69.

Hausmanowa-Petrusewicz I, Kowalska-Oledzka E, Miller FW, Jarzabek-Chorzelska M, Targoff IN, Blaszczyk-Kostanecka M, Jablonska S (1997) Clinical, serologic, and immunogenetic features in Polish patients with idiopathic inflammatory myopathies. Arthritis Rheum 40:1257–1266PubMedCrossRef

70.

Komura K, Fujimoto M, Matsushita T, Kaji K, Kondo M, Hirano T, Orito H, Horikawa M, Hamaguchi Y, Hasegawa M et al (2005) Prevalence and clinical characteristics of anti-Mi-2 antibodies in Japanese patients with dermatomyositis. J Dermatol Sci 40:215–217PubMedCrossRef

71.

Ghirardello A, Zampieri S, Iaccarino L, Tarricone E, Bendo R, Gambari PF, Doria A (2005) Anti-Mi-2 antibodies. Autoimmunity 38:79–83PubMedCrossRef

72.

Ronnelid J, Barbasso Helmers S, Storfors H, Grip K, Ronnblom L, Franck-Larsson K, Nordmark G, Lundberg IE (2009) Use of a commercial line blot assay as a screening test for autoantibodies in inflammatory myopathies. Autoimmun Rev 9:58–61PubMedCrossRef

73.

Ghirardello A, Rampudda M, Ekholm L, Bassi N, Tarricone E, Zampieri S, Zen M, Vattemi GA, Lundberg IE, Doria A (2010) Diagnostic performance and validation of autoantibody testing in myositis by a commercial line blot assay. Rheumatology (Oxford) 49:2370–2374CrossRef

74.

Hamaguchi Y, Kuwana M, Hoshino K, Hasegawa M, Kaji K, Matsushita T, Komura K, Nakamura M, Kodera M, Suga N et al (2011) Clinical correlations with dermatomyositis-specific autoantibodies in adult Japanese patients with dermatomyositis: a multicenter cross-sectional study. Arch Dermatol 147:391–398PubMedCrossRef

75.

Ceribelli A, Fredi M, Taraborelli M, Cavazzana I, Franceschini F, Quinzanini M, Tincani A, Ross SJ, Chan JY, Pauley BA et al (2012) Anti-MJ/NXP-2 autoantibody specificity in a cohort of adult Italian patients with polymyositis/dermatomyositis. Arthritis Res Ther 14:R97PubMedPubMedCentralCrossRef

76.

Muro Y, Sugiura K, Akiyama M (2013) A new ELISA for dermatomyositis autoantibodies: rapid introduction of autoantigen cDNA to recombinant assays for autoantibody measurement. Clin Dev Immunol 2013:856815PubMedPubMedCentralCrossRef

77.

Petri MH, Satoh M, Martin-Marquez BT, Vargas-Ramirez R, Jara LJ, Saavedra MA, Cruz-Gonzalez C, Andrade-Ortega L, Vera-Lastra OL, Salazar-Paramo M et al (2013) Implications in the difference of anti-Mi-2 and -p155/140 autoantibody prevalence in two dermatomyositis cohorts from Mexico City and Guadalajara. Arthritis Res Ther 15:R48PubMedPubMedCentralCrossRef

78.

Okada S, Weatherhead E, Targoff IN, Wesley R, Miller FW (2003) Global surface ultraviolet radiation intensity may modulate the clinical and immunologic expression of autoimmune muscle disease. Arthritis Rheum 48:2285–2293PubMedCrossRef

79.

Love LA, Weinberg CR, McConnaughey DR, Oddis CV, Medsger TA Jr, Reveille JD, Arnett FC, Targoff IN, Miller FW (2009) Ultraviolet radiation intensity predicts the relative distribution of dermatomyositis and anti-Mi-2 autoantibodies in women. Arthritis Rheum 60:2499–2504PubMedPubMedCentralCrossRef

80.

Euwer RL, Sontheimer RD (1991) Amyopathic dermatomyositis (dermatomyositis sine myositis). Presentation of six new cases and review of the literature. J Am Acad Dermatol 24:959–966PubMedCrossRef

81.

Gerami P, Schope JM, McDonald L, Walling HW, Sontheimer RD (2006) A systematic review of adult-onset clinically amyopathic dermatomyositis (dermatomyositis sine myositis): a missing link within the spectrum of the idiopathic inflammatory myopathies. J Am Acad Dermatol 54:597–613PubMedCrossRef

82.

Fujikawa K, Kawakami A, Kaji K, Fujimoto M, Kawashiri S, Iwamoto N, Aramaki T, Ichinose K, Tamai M, Kamachi M et al (2009) Association of distinct clinical subsets with myositis-specific autoantibodies towards anti-155/140-kDa polypeptides, anti-140-kDa polypeptides, and anti-aminoacyl tRNA synthetases in Japanese patients with dermatomyositis: a single-centre, cross-sectional study. Scand J Rheumatol 38:263–267PubMedCrossRef

83.

Gono T, Kawaguchi Y, Satoh T, Kuwana M, Katsumata Y, Takagi K, Masuda I, Tochimoto A, Baba S, Okamoto Y et al (2010) Clinical manifestation and prognostic factor in anti-melanoma differentiation-associated gene 5 antibody-associated interstitial lung disease as a complication of dermatomyositis. Rheumatology (Oxford) 49:1713–1719CrossRef

84.

Gono T, Kawaguchi Y, Ozeki E, Ota Y, Satoh T, Kuwana M, Hara M, Yamanaka H (2011) Serum ferritin correlates with activity of anti-MDA5 antibody-associated acute interstitial lung disease as a complication of dermatomyositis. Mod Rheumatol 21:223–227PubMedCrossRef

85.

Kobayashi I, Okura Y, Yamada M, Kawamura N, Kuwana M, Ariga T (2011) Anti-melanoma differentiation-associated gene 5 antibody is a diagnostic and predictive marker for interstitial lung diseases associated with juvenile dermatomyositis. J Pediatr 158:675–677PubMedCrossRef

86.

Chen F, Wang D, Shu X, Nakashima R, Wang G (2012) Anti-MDA5 antibody is associated with A/SIP and decreased T cells in peripheral blood and predicts poor prognosis of ILD in Chinese patients with dermatomyositis. Rheumatol Int 32:3909–3915PubMedCrossRef

87.

Muro Y, Sugiura K, Hoshino K, Akiyama M (2011) Disappearance of anti-MDA-5 autoantibodies in clinically amyopathic DM/interstitial lung disease during disease remission. Rheumatology (Oxford) 51:800–804CrossRef

88.

Cao H, Pan M, Kang Y, Xia Q, Li X, Zhao X, Shi R, Lou J, Zhou M, Kuwana M et al (2012) Clinical manifestations of dermatomyositis and clinically amyopathic dermatomyositis patients with positive expression of anti-melanoma differentiation-associated gene 5 antibody. Arthritis Care Res (Hoboken) 64:1602–1610CrossRef

89.

Fiorentino D, Chung L, Zwerner J, Rosen A, Casciola-Rosen L (2011) The mucocutaneous and systemic phenotype of dermatomyositis patients with antibodies to MDA5 (CADM-140): a retrospective study. J Am Acad Dermatol 65:25–34PubMedPubMedCentralCrossRef

90.

Hall JC, Casciola-Rosen L, Samedy LA, Werner J, Owoyemi K, Danoff SK, Christopher-Stine L (2013) Anti-MDA5-associated dermatomyositis: expanding the clinical spectrum. Arthritis Care Res (Hoboken) 65:1307–1315CrossRef

91.

Ceribelli A, Fredi M, Taraborelli M, Cavazzana I, Tincani A, Selmi C, Chan JY, Chan EK, Satoh M, Franceschini F (2014) Prevalence and clinical significance of anti-MDA5 antibodies in European patients with polymyositis/dermatomyositis. Clin Exp Rheumatol 32:891–897PubMed

92.

Labrador-Horrillo M, Martinez MA, Selva-O'Callaghan A, Trallero-Araguas E, Balada E, Vilardell-Tarres M, Juarez C (2014) Anti-MDA5 antibodies in a large Mediterranean population of adults with dermatomyositis. J Immunol Res 2014:290797PubMedPubMedCentralCrossRef

93.

Sato S, Kuwana M, Fujita T, Suzuki Y (2013) Anti-CADM-140/MDA5 autoantibody titer correlates with disease activity and predicts disease outcome in patients with dermatomyositis and rapidly progressive interstitial lung disease. Mod Rheumatol 23:496–502PubMedCrossRef

94.

Targoff IN, Trieu EP, Levy-Neto M, Prasertsuntarasai T, Miller FW (2006) Autoantibodies to transcriptional intermediary factor 1-gamma (TIF1-γ) in dermatomyositis. Arthritis Rheum 54(Suppl):S518

95.

Satoh M, Chan JY, Ross SJ, Li Y, Yamasaki Y, Yamada H, Mercado MV, Petri MH, Jara LJ, Saavedra MA et al (2012) Autoantibodies to transcription intermediary factor (TIF)1beta associated with dermatomyositis. Arthritis Res Ther 14:R79PubMedPubMedCentralCrossRef

96.

Herquel B, Ouararhni K, Khetchoumian K, Ignat M, Teletin M, Mark M, Bechade G, Van Dorsselaer A, Sanglier-Cianferani S, Hamiche A et al (2011) Transcription cofactors TRIM24, TRIM28, and TRIM33 associate to form regulatory complexes that suppress murine hepatocellular carcinoma. Proc Natl Acad Sci U S A 108:8212–8217PubMedPubMedCentralCrossRef

97.

Gunawardena H, Wedderburn LR, North J, Betteridge Z, Dunphy J, Chinoy H, Davidson JE, Cooper RG, McHugh NJ (2008) Clinical associations of autoantibodies to a p155/140 kDa doublet protein in juvenile dermatomyositis. Rheumatology (Oxford) 47:324–328CrossRef

98.

Trallero-Araguas E, Labrador-Horrillo M, Selva-O'Callaghan A, Martinez MA, Martinez-Gomez X, Palou E, Rodriguez-Sanchez JL, Vilardell-Tarres M (2010) Cancer-associated myositis and anti-p155 autoantibody in a series of 85 patients with idiopathic inflammatory myopathy. Medicine (Baltimore) 89:47–52CrossRef

99.

Kaji K, Fujimoto M, Hasegawa M, Kondo M, Saito Y, Komura K, Matsushita T, Orito H, Hamaguchi Y, Yanaba K et al (2007) Identification of a novel autoantibody reactive with 155 and 140 kDa nuclear proteins in patients with dermatomyositis: an association with malignancy. Rheumatology (Oxford) 46:25–28CrossRef

100.

Kang EH, Nakashima R, Mimori T, Kim J, Lee YJ, Lee EB, Song YW (2010) Myositis autoantibodies in Korean patients with inflammatory myositis: anti-140-kDa polypeptide antibody is primarily associated with rapidly progressive interstitial lung disease independent of clinically amyopathic dermatomyositis. BMC Musculoskelet Disord 11:223PubMedPubMedCentralCrossRef

101.

Ikeda N, Takahashi K, Yamaguchi Y, Inasaka M, Kuwana M, Ikezawa Z (2011) Analysis of dermatomyositis-specific autoantibodies and clinical characteristics in Japanese patients. J Dermatol 38:973–979PubMedCrossRef

102.

Targoff IN, Trieu EP, Levy-Neto M, Fertig N, Oddis CV (2007) Sera with autoantibodies to the MJ antigen react with NXP2. Arthritis Rheum 56:S787

103.

Mimura Y, Takahashi K, Kawata K, Akazawa T, Inoue N (2010) Two-step colocalization of MORC3 with PML nuclear bodies. J Cell Sci 123:2014–2024PubMedCrossRef

104.

Kimura Y, Sakai F, Nakano O, Kisaki O, Sugimoto H, Sawamura T, Sadano H, Osumi T (2002) The newly identified human nuclear protein NXP-2 possesses three distinct domains, the nuclear matrix-binding, RNA-binding, and coiled-coil domains. J Biol Chem 277:20611–20617PubMedCrossRef

105.

Takahashi K, Yoshida N, Murakami N, Kawata K, Ishizaki H, Tanaka-Okamoto M, Miyoshi J, Zinn AR, Shime H, Inoue N (2007) Dynamic regulation of p53 subnuclear localization and senescence by MORC3. Mol Biol Cell 18:1701–1709PubMedPubMedCentralCrossRef

106.

Oddis CV, Fertig N, Goel A, Espada G, Confalone Gregorian M, Maldonado Cocco JA, Londino AV (1997) Clinical and serological characterization of the anti-MJ antibody in childhood myositis. Arthritis Rheum 40:S139

107.

Espada G, Maldonado Cocco JA, Fertig N, Oddis CV (2009) Clinical and serologic characterization of an Argentine pediatric myositis cohort: identification of a novel autoantibody (anti-MJ) to a 142-kDa protein. J Rheumatol 36:2547–2551PubMedCrossRef

108.

Gunawardena H, Wedderburn LR, Chinoy H, Betteridge ZE, North J, Ollier WE, Cooper RG, Oddis CV, Ramanan AV, Davidson JE et al (2009) Autoantibodies to a 140-kD protein in juvenile dermatomyositis are associated with calcinosis. Arthritis Rheum 60:1807–1814PubMedPubMedCentralCrossRef

109.

Betteridge ZE, Gunawardena H, Chinoy H, Venkovsky J, Allard SA, Gordon PA, Cooper RG, McHugh NJ (2009) Autoantibodies to the p140 autoantigen NXP-2 in adult dermatomyositis. Arthritis Rheum 60:S304

110.

Ichimura Y, Matsushita T, Hamaguchi Y, Kaji K, Hasegawa M, Tanino Y, Inokoshi Y, Kawai K, Kanekura T, Habuchi M et al (2012) Anti-NXP2 autoantibodies in adult patients with idiopathic inflammatory myopathies: possible association with malignancy. Ann Rheum Dis 71:710–713PubMedCrossRef

111.

Fiorentino DF, Chung LS, Christopher-Stine L, Zaba L, Li S, Mammen AL, Rosen A, Casciola-Rosen L (2013) Most patients with cancer-associated dermatomyositis have antibodies to nuclear matrix protein NXP-2 or transcription intermediary factor 1gamma. Arthritis Rheum 65:2954–2962PubMedPubMedCentralCrossRef

112.

Troyanov Y, Targoff IN, Payette MP, Raynauld JP, Chartier S, Goulet JR, Bourre-Tessier J, Rich E, Grodzicky T, Fritzler MJ et al (2014) Redefining dermatomyositis: a description of new diagnostic criteria that differentiate pure dermatomyositis from overlap myositis with dermatomyositis features. Medicine (Baltimore) 93:318–332CrossRef

113.

Valenzuela A, Chung L, Casciola-Rosen L, Fiorentino D (2014) Identification of clinical features and autoantibodies associated with calcinosis in dermatomyositis. JAMA Dermatol 150:724–729PubMedPubMedCentralCrossRef

114.

Betteridge Z, Gunawardena H, North J, Slinn J, McHugh N (2007) Identification of a novel autoantibody directed against small ubiquitin-like modifier activating enzyme in dermatomyositis. Arthritis Rheum 56:3132–3137PubMedCrossRef

115.

Betteridge ZE, Gunawardena H, Chinoy H, North J, Ollier WE, Cooper RG, McHugh NJ (2009) Clinical and human leucocyte antigen class II haplotype associations of autoantibodies to small ubiquitin-like modifier enzyme, a dermatomyositis-specific autoantigen target, in UK Caucasian adult-onset myositis. Ann Rheum Dis 68:1621–1625PubMedCrossRef

116.

Tarricone E, Ghirardello A, Rampudda M, Bassi N, Punzi L, Doria A (2012) Anti-SAE antibodies in autoimmune myositis: identification by unlabelled protein immunoprecipitation in an Italian patient cohort. J Immunol Methods 384:128–134PubMedCrossRef

117.

Fujimoto M, Matsushita T, Hamaguchi Y, Kaji K, Asano Y, Ogawa F, Yamaoka T, Fujikawa K, Tsukada T, Sato K et al (2013) Autoantibodies to small ubiquitin-like modifier activating enzymes in Japanese patients with dermatomyositis: comparison with a UK Caucasian cohort. Ann Rheum Dis 72:151–153PubMedCrossRef

118.

Muro Y, Sugiura K, Akiyama M (2013) Low prevalence of anti-small ubiquitin-like modifier activating enzyme antibodies in dermatomyositis patients. Autoimmunity 46:279–284PubMedCrossRef

119.

Satoh M, Tanaka S, Chan EK (2015) The uses and misuses of multiplex autoantibody assays in systemic autoimmune rheumatic diseases. Front Immunol 6:181PubMedPubMedCentralCrossRef

120.

Satoh M, Chan JY, Ross SJ, Ceribelli A, Cavazzana I, Franceschini F, Li Y, Reeves WH, Sobel ES, Chan EK (2011) Autoantibodies to survival of motor neuron (SMN) complex in patients with polymyositis—immunoprecipitation of D-E-F-G without other components of small nuclear ribonucleoproteins. Arthritis Rheum 63:1972–1978PubMedPubMedCentralCrossRef

121.

Lanzavecchia A (1995) How can cryptic epitopes trigger autoimmunity? J Exp Med 181:1945–1948PubMedCrossRef

122.

Tan EM (2001) Autoantibodies as reporters identifying aberrant cellular mechanisms in tumorigenesis. J Clin Invest 108:1411–1415PubMedPubMedCentralCrossRef

123.

Abu-Shakra M, Buskila D, Ehrenfeld M, Conrad K, Shoenfeld Y (2001) Cancer and autoimmunity: autoimmune and rheumatic features in patients with malignancies. Ann Rheum Dis 60:433–441PubMedPubMedCentralCrossRef

124.

Reuschenbach M, von Knebel DM, Wentzensen N (2009) A systematic review of humoral immune responses against tumor antigens. Cancer Immunol Immunother 58:1535–1544PubMedPubMedCentralCrossRef

125.

Joseph CG, Darrah E, Shah AA, Skora AD, Casciola-Rosen LA, Wigley FM, Boin F, Fava A, Thoburn C, Kinde I et al (2014) Association of the autoimmune disease scleroderma with an immunologic response to cancer. Science 343:152–157PubMedCrossRef

126.

Vincent DF, Yan KP, Treilleux I, Gay F, Arfi V, Kaniewski B, Marie JC, Lepinasse F, Martel S, Goddard-Leon S et al (2009) Inactivation of TIF1gamma cooperates with Kras to induce cystic tumors of the pancreas. PLoS Genet 5, e1000575PubMedPubMedCentralCrossRef

127.

Aucagne R, Droin N, Paggetti J, Lagrange B, Largeot A, Hammann A, Bataille A, Martin L, Yan KP, Fenaux P et al (2011) Transcription intermediary factor 1gamma is a tumor suppressor in mouse and human chronic myelomonocytic leukemia. J Clin Invest 121:2361–2370PubMedPubMedCentralCrossRef

128.

Forrester NA, Patel RN, Speiseder T, Groitl P, Sedgwick GG, Shimwell NJ, Seed RI, Catnaigh PO, McCabe CJ, Stewart GS et al (2012) Adenovirus E4orf3 targets transcriptional intermediary factor 1gamma for proteasome-dependent degradation during infection. J Virol 86:3167–3179PubMedPubMedCentralCrossRef

129.

Herquel B, Ouararhni K, Martianov I, Le Gras S, Ye T, Keime C, Lerouge T, Jost B, Cammas F, Losson R et al (2013) Trim24-repressed VL30 retrotransposons regulate gene expression by producing noncoding RNA. Nat Struct Mol Biol 20:339–346PubMedCrossRef

130.

Dong X, Hamilton KJ, Satoh M, Wang J, Reeves WH (1994) Initiation of autoimmunity to the p53 tumor suppressor protein by complexes of p53 and SV40 large T antigen. J Exp Med 179:1243–1252PubMedCrossRef

131.

Satoh M, Ceribelli A, Chan EK (2012) Common pathways of autoimmune inflammatory myopathies and genetic neuromuscular disorders. Clin Rev Allergy Immunol 42:16–25PubMedCrossRef

Titel: A Comprehensive Overview on Myositis-Specific Antibodies: New and Old Biomarkers in Idiopathic Inflammatory Myopathy
verfasst von: Minoru Satoh
Shin Tanaka
Angela Ceribelli
S. John Calise
Edward K. L. Chan
Publikationsdatum: 30.09.2015
Verlag: Springer US
Erschienen in: Clinical Reviews in Allergy & Immunology / Ausgabe 1/2017
Print ISSN: 1080-0549
Elektronische ISSN: 1559-0267
DOI: https://doi.org/10.1007/s12016-015-8510-y

Neu im Fachgebiet HNO

„Übersichtlicher Wegweiser“: Lauterbachs umstrittener Klinik-Atlas ist online

17.05.2024 Klinik aktuell Nachrichten

Sie sei „ethisch geboten“, meint Gesundheitsminister Karl Lauterbach: mehr Transparenz über die Qualität von Klinikbehandlungen. Um sie abzubilden, lässt er gegen den Widerstand vieler Länder einen virtuellen Klinik-Atlas freischalten.

Betalaktam-Allergie: praxisnahes Vorgehen beim Delabeling

16.05.2024 Pädiatrische Allergologie Nachrichten

Die große Mehrheit der vermeintlichen Penicillinallergien sind keine. Da das „Etikett“ Betalaktam-Allergie oft schon in der Kindheit erworben wird, kann ein frühzeitiges Delabeling lebenslange Vorteile bringen. Ein Team von Pädiaterinnen und Pädiatern aus Kanada stellt vor, wie sie dabei vorgehen.

Klinikreform soll zehntausende Menschenleben retten

15.05.2024 Klinik aktuell Nachrichten

Gesundheitsminister Lauterbach hat die vom Bundeskabinett beschlossene Klinikreform verteidigt. Kritik an den Plänen kommt vom Marburger Bund. Und in den Ländern wird über den Gang zum Vermittlungsausschuss spekuliert.

Eingreifen von Umstehenden rettet vor Erstickungstod

15.05.2024 Fremdkörperaspiration Nachrichten

Wer sich an einem Essensrest verschluckt und um Luft ringt, benötigt vor allem rasche Hilfe. Dass Umstehende nur in jedem zweiten Erstickungsnotfall bereit waren, diese zu leisten, ist das ernüchternde Ergebnis einer Beobachtungsstudie aus Japan. Doch es gibt auch eine gute Nachricht.

Update HNO

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert – ganz bequem per eMail.

Newsletter bestellen

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

A Comprehensive Overview on Myositis-Specific Antibodies: New and Old Biomarkers in Idiopathic Inflammatory Myopathy

Abstract

Neu im Fachgebiet HNO

„Übersichtlicher Wegweiser“: Lauterbachs umstrittener Klinik-Atlas ist online

Betalaktam-Allergie: praxisnahes Vorgehen beim Delabeling

Klinikreform soll zehntausende Menschenleben retten

Eingreifen von Umstehenden rettet vor Erstickungstod

Update HNO

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2017

Idiopathic Inflammatory Myopathies: an Update on Classification and Treatment with Special Focus on Juvenile Forms

Modern Therapies for Idiopathic Inflammatory Myopathies (IIMs): Role of Biologics

Renal Involvement in Idiopathic Inflammatory Myopathies

Thymic Germinal Centers and Corticosteroids in Myasthenia Gravis: an Immunopathological Study in 1035 Cases and a Critical Review

Review on Toll-Like Receptor Activation in Myasthenia Gravis: Application to the Development of New Experimental Models

The Clinical Features of Myositis-Associated Autoantibodies: a Review

Neu im Fachgebiet HNO

„Übersichtlicher Wegweiser“: Lauterbachs umstrittener Klinik-Atlas ist online

Betalaktam-Allergie: praxisnahes Vorgehen beim Delabeling

Klinikreform soll zehntausende Menschenleben retten

Eingreifen von Umstehenden rettet vor Erstickungstod

Update HNO